US EditionTQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned by Bristol Myers Squibb. Financial terms have not been disclosed. The acquisition expands TQx’s access to intellectual property and licensing agreements that will support the development of its decentralised, automated cell […]
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform - Pharmafile
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned by Bristol Myers Squibb. Financial terms have not been disclosed. The acquisition expands TQx’s access to intellectual property and licensing agreements that will support the development of its decentralised, automated cell […] The post TQ Therapeutics acquires Juno GmbH to supp…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
